(Redirected from Yasmin (drug))
Combination drug
 Ethinylestradiol | |
 Drospirenone | |
| Combination of | |
|---|---|
| Ethinylestradiol | Estrogen |
| Drospirenone | Progestogen; Progestin; Antimineralocorticoid; Antiandrogen |
| Clinical data | |
| Trade names | With 30 μg ethinylestradiol: Yasmin, others With 20 μg ethinylestradiol: Yaz, Yasminelle, others |
| Other names | EE/DRSP; drospirenone/estradiol; drospirenone/ethinyl estradiol |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a601050 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Ethinylestradiol/drospirenone (EE/DRSP), sold under the brand name Yasmin among others, is a combination of ethinylestradiol (EE), an estrogen, and drospirenone (DRSP), a progestin, antimineralocorticoid, and antiandrogen, which is used as a birth control pill to prevent pregnancy in women. It is also indicated for the treatment of moderate acne, premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and dysmenorrhea (painful menstruation) in women. The medication is taken by mouth and contains 30 μg EE and 3 mg DRSP per tablet (brand names Yasmin, others) or 20 μg EE and 3 mg DRSP per tablet (brand names Yaz, Yasminelle, Nikki, others). A formulation with levomefolic acid (vitamin B9) has also been marketed (brand names Beyaz, Safyral, others), with similar indications. EE/DRSP is marketed widely throughout the world.
In 2021, it was the 152nd most commonly prescribed medication in the United States, with more than 3 million prescriptions.
See also
- Ethinylestradiol/drospirenone/levomefolic acid
- Ethinylestradiol/drospirenone/prasterone
- Estradiol/drospirenone
- List of combined sex-hormonal preparations § Estrogens and progestogens
References
- "Drospirenone / estradiol (Angeliq) Use During Pregnancy". Drugs.com. 6 September 2018. Retrieved 18 March 2020.
- "Ethinylestradiol/Drospirenone". AdisInsight. Springer Nature Switzerland AG.
- ^ "Drospirenone/Ethinylestradiol low-dose - Bayer HealthCare Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
- ^ Bayer HealthCare Pharmaceuticals Inc. "Highlights of Prescribing Information: Yasmin" (PDF). U.S. Food and Drug Administration.
- ^ Bayer HealthCare Pharmaceuticals Inc. "Highlights of Prescribing Information: Yaz" (PDF). U.S. Food and Drug Administration. Retrieved 31 October 2017.
- Keam SJ, Wagstaff AJ (2003). "Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive". Treatments in Endocrinology. 2 (1): 49–70. doi:10.2165/00024677-200302010-00005. PMID 15871554. S2CID 209144694.
- "Ethinylestradiol/Drospirenone/Folic acid". AdisInsight. Springer Nature Switzerland AG.
- Bayer HealthCare Pharmaceuticals Inc. "Highlights of Prescribing Information: Beyaz" (PDF). U.S. Food and Drug Administration.
- "Drospirenone Uses, Side Effects & Warnings". Drugs.com.
- "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- "Drospirenone; Ethinyl Estradiol - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 | This drug article relating to the genito-urinary system is a stub. You can help Knowledge by expanding it. |